A Phase I Study of ABT-888 in Combination With Temozolomide (TMZ) in Subjects With Non-Hematologic Malignancies (NHM) and Metastatic Melanoma (MM).

Trial Profile

A Phase I Study of ABT-888 in Combination With Temozolomide (TMZ) in Subjects With Non-Hematologic Malignancies (NHM) and Metastatic Melanoma (MM).

Completed
Phase of Trial: Phase I

Latest Information Update: 11 May 2017

At a glance

  • Drugs Veliparib (Primary) ; Temozolomide
  • Indications Advanced breast cancer; Fallopian tube cancer; Liver cancer; Malignant melanoma; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 11 May 2017 Results evaluating the mass balance of veliparib and drug drug interaction between veliparib and temozolomide, published in the Clinical Pharmacokinetics
    • 12 Jan 2012 Additional lead trial investigator (Bhardwaj Desai) identified as reported by ClinicalTrials.gov
    • 22 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top